Royalty Pharma

Royalty Pharma Plc provides drug development services. The firm operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Royalty Pharma reports robust Q4 performance and strategic growth outlook

Royalty Pharma's Q4 2022 earnings call highlighted strong financial performance, efficient cash flow management, and strategic acquisitions. While facing challenges in certain product sales trajectories and market conditions, the company remains focused on innovation and long-term success in the life sciences industry.

Royalty Pharma reports robust Q1 performance and raises capital deployment guidance

Royalty Pharma's Q1 2023 earnings call highlighted strong financial performance, strategic portfolio expansion, and disciplined capital deployment. The company's robust financial health, selective investment approach, and optimistic outlook on market opportunities position them for continued growth. Challenges in deal flow prediction and balancing investments underscore the need for strategic planning and adaptability in a competitive market landscape.

Royalty Pharma (RPRX) reports robust Q2 results amidst regulatory challenges

Royalty Pharma's Q2 performance reflects resilience and growth, supported by strategic initiatives and strong financial metrics. While facing challenges related to regulatory impacts and investor sentiment, the company is focused on leveraging opportunities in attracting investors, educating about its business model, and expanding capital deployment for future growth.

Royalty Pharma reports robust Q3 performance and optimistic growth outlook

Royalty Pharma's Q3 earnings call showcased strong financial performance, active capital allocation, and a focus on shareholder value creation. The company's robust financial model, emphasis on tailored solutions, and optimism about portfolio growth position it well for future opportunities.

Royalty Pharma reports robust 2023 performance and outlines growth strategies

Royalty Pharma's strong performance in 2023 and strategic acquisitions position the company for continued growth in 2024.
Challenges include legal uncertainties and managing shareholder turnover, while opportunities exist in innovative investments and enhanced investor relations.
The company's focus on transparency and attracting long-term investors underscores its commitment to sustainable growth.

Royalty Pharma reports strong Q1 growth and strategic acquisitions

Royalty Pharma's Q1 performance reflects growth and strategic acquisitions, positioning the company for future success.
While facing challenges related to safety concerns and short-term portfolio fluctuations, Royalty Pharma remains focused on growth.
The company's emphasis on identifying high-potential drugs and upcoming milestones underscores a promising outlook for investors.

Royalty Pharma reports robust Q3 growth and eyes innovative therapies

Royalty Pharma's Q3 performance reflects strong growth and strategic decision-making, positioning the company for continued success.
Despite challenges in market penetration and administration, Royalty Pharma remains optimistic about its growth prospects and innovative therapies.
The company's focus on synthetic royalties, strategic acquisitions, and financial discipline underpin its resilience and potential for future expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.

Royalty Pharma plc (RPRX) CEO Pablo Legorreta on Q3 2021 Results - Earning Call Transcript

Royalty Pharma (RPRX) delivered earnings and revenue surprises of 5.80% and 3.18%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Royalty Pharma (RPRX) Tops Q3 Earnings and Revenue Estimates

RPRX buys royalties of high-profile assets.

Royalty Pharma Provides Unique Diversity To A Biopharma Portfolio

NEW YORK, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter of 2021 financial results on Wednesday, November 10, 2021 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day.

Royalty Pharma to Announce Third-Quarter 2021 Financial Results on November 10, 2021

NEW YORK, Oct. 15, 2021 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2021 of $0.17 per Class A ordinary share.

Royalty Pharma Declares Fourth-Quarter 2021 Dividend

Regeneron Pharmaceuticals

SAGE Therapeutics

With the US Q3 earnings season just getting started, there are a few biotech stocks that present an exciting opportunity for value investors. Some of these stocks look significantly undervalued after a decline in their stock prices.

Top 3 undervalued US biotech stocks to buy

Drug development, both a lucrative and a risky segment. Royalty Pharma plc (NASDAQ: RPRX) offers a middle ground for its investors.

Wall Street Journal Creates A Pitch In Favor Of Royalty Pharma

Royalty Pharma's (RPRX) CEO Pablo Legorreta on Q2 2021 Results - Earnings Call Transcript

Royalty Pharma (RPRX) delivered earnings and revenue surprises of 1.43% and 0.10%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Royalty Pharma (RPRX) Q2 Earnings and Revenues Surpass Estimates

Shares of Royalty Pharma (NASDAQ:RPRX) rose 3.8% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were down 26.26% year over year to $0.73, which beat the estimate of $0.69.

Recap: Royalty Pharma Q2 Earnings

NEW YORK, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the second quarter of 2021 and raised full-year 2021 guidance for Adjusted Cash Receipts( 1) (a non-GAAP financial measure).

Royalty Pharma Reports Second Quarter 2021 Results

Royalty Pharma (RPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Royalty Pharma (RPRX) Q2 Earnings Expected to Decline

NEW YORK, July 19, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter of 2021 financial results on Wednesday, August 11, 2021 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day.

Royalty Pharma to Announce Second-Quarter 2021 Financial Results on August 11, 2021

NEW YORK, July 16, 2021 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2021 of $0.17 per class A ordinary share.

Royalty Pharma Declares Third-Quarter 2021 Dividend

NEW YORK, July 15, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today that it has priced an offering of $1.3 billion of senior unsecured notes, comprised of the following (collectively, the “Notes”):

Royalty Pharma Announces Pricing of $1.3 Billion of Senior Unsecured Notes, Including $600 Million Social Bond

Morphosys AG - ADR

MorphoSys AG (NASDAQ: MOR) has agreed to acquire Constellation Pharmaceuticals Inc (NASDAQ: CNST) for $34/share in cash, representing a total equity value of $1.7 billion. The transaction is expected to close in the third quarter of 2021.

MorphoSys to Acquire Constellation Pharma at $34/Share; Enters $2B Strategic Funding with Royalty Pharma

NEW YORK and PLANEGG, Germany, June 02, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and MorphoSys AG (FSE: MOR; Nasdaq: MOR) today announced a $2.025 billion strategic funding partnership as part of MorphoSys' $1.7 billion acquisition of Constellation Pharmaceuticals (Nasdaq: CNST). This partnership is expected to fuel the expansion of the combined company's capabilities to help enable the development and potential approvals of important cancer treatments.

Royalty Pharma Announces $2.025 Billion Strategic Funding Partnership With MorphoSys

Royalty Pharma plc (RPRX) CEO Pablo Legorreta on Q1 2021 Results - Earnings Call Transcript

NEW YORK, May 11, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the first quarter of 2021 and raised full-year 2021 guidance for Adjusted Cash Receipts( 1) (a non-GAAP financial measure).

Royalty Pharma Reports First Quarter 2021 Results

Royalty Pharma is a new type of healthcare company.

Royalty Pharma: A Potentially Long-Term Dividend Investment

NEW YORK, April 21, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2021 financial results on Tuesday, May 11, 2021 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day.

Royalty Pharma to Announce First-Quarter 2021 Financial Results on May 11, 2021

NEW YORK, April 21, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced a collaboration with MSCI Inc. (NYSE: MSCI), a leading provider of critical decision support tools and services for the global investment community, to expand MSCI's thematic index suite with the launch of new indexes that aim to capture long-term, cutting edge themes that will disrupt the life sciences, biotechnology and pharmaceutical industry groups.

Royalty Pharma Announces Strategic Alliance With MSCI to Launch Life Sciences Indexes

NEW YORK, April 15, 2021 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2021 of $0.17 per class A share.

Royalty Pharma Declares Second-Quarter 2021 Dividend

SYF vs. RPRX: Which Stock Is the Better Value Option?

SYF or RPRX: Which Is the Better Value Stock Right Now?

Dicerna Pharmaceuticals

Royalty Pharma plc (NASDAQ: RPRX) has acquired  Dicerna Pharmaceuticals Inc's (NASDAQ: DRNA) royalty interest in Oxlumo (lumasiran) for an upfront cash payment of $180 million and up to $60 million in contingent sales-based milestone payments. The FDA and European Medicines Agency have approved Oxlumo (EMA) for the treatment of primary hyperoxaluria (PH) type 1 and is marketed by Alnylam Pharmaceuticals Inc (NASDAQ: ALNY).

News for Royalty Pharma Stock (RPRX)